Stereotactic Body Radiotherapy for the Treatment of OPD

Prior treatment

• Progressing or newly diagnosed brain metastases identified at the time of trial entry, not amenable to radical surgery or SRS. Previously treated brain metastases (i.e palliative radiotherapy or systemic therapy) which have remained clinically and radiologically stable for ≥ 6 months are permissible.
• Prior radiotherapy near the oligoprogressive lesion precluding ablative SBRT. Suitability of lesions for ablative SBRT as part of the trial defined in section 4.1 of this document and will be determined by the HALT virtual MDT
• Co-morbidities considered clinically precluding the safe use of SBRT (as detailed in the HALT radiotherapy planning and delivery guidelines).

Other illness

• \> 5 extracranial sites of progressive disease

Other

• Any psychological, sociological or geographical issue potentially hampering compliance with the study
• Pregnancy

• Male or female, ≥ 16 years of age
• Established histological diagnosis of advanced NSCLC, not suitable for radical treatment, with defined actionable mutation receiving targeted TKI therapy
• Clinical and/or radiologically confirmed response to TKI therapy (assessed locally usually 2-3 months post commencing TKI)
• Confirmed OPD defined as ≤ 5 extracranial sites of progressive disease. All sites must be visible, imaging defined targets and suitable for treatment with SBRT as determined by the virtual multi-disciplinary team (MDT) and in accordance with the HALT Radiotherapy planning and delivery guidance document.
• Adequate baseline organ function to allow SBRT to all relevant targets
• Predicted life expectancy ≥ 6 months
• Karnofsky Index ≥ 60% and ECOG 0-2
• Provision of written informed consent